Sodium Chloride 0.9% w/v. Nasal drops, 20 ml
2 drops in each nostril up to 4 times/d.
For the relief of nasal congestion in children and infants
C/I: hypersens.
peroxisome proliferator-activated receptor delta (PPARδ) agonist. Seladelpar 10 mg. Caps: 30 X 10 mg
Recomm. dose: 10 mg once daily.
For prim. biliary cholangitis (PBC) in combin. with ursodeoxycholic acid (UDCA) in adlts who have an inadequate resp. to UDCA alone, or as monother. in those unable to toler. UDCA.
C/I: Hypersens.
Antivirals. Bulevirtide 2 mg/ml. Vial. Pwder. for sol. for inj. 30 X 2 mg
Manage the underlying hepatitis B virus (HBV) infect. simultan. according to the official guidelines. To be admin. 1/d by SC inject. Recomm. dosage is 2 mg 1/d as long as clin. benef. is seen.
Tmt.of chronic hepatitis delta virus (HDV) infect. in plasma (or serum) HDV-RNA posit. adults with compensated liver dis.
C/I: Hypersens.
Drug class Cross-linked polyacrylic acid sodium salt, hydroxy propyl
methyl cellulose (HPMC), titanium dioxide, cellulose acetate
phthalate, hydroxypropyl cellulose, chitosan, diethyl
phthalate, polyvinyl alcohol polyethylene copolymer
(Kollicoat), triethyl citrate, cellulose acetate, acetyl tributyl
citrate.
Caps. X 56
1 cap. before meal X 2/d
Reducing BW in pts with 25 < BMI < 40 in conjunction with diet and exercise.
C/I: Hypersens. Pregn
Corticosteroid. Budesonide 2 mg. Canister with 14 X of 1.2 g
One actuation of 2 mg /d
Tmt of act. ulcerative colitis limited to the rectum and the sigmoid colon
C/I: Hypersens. /hepatic cyrrhosis
Anti-CD20, Human Monoclonal Antibody. Ocrelizumab 40 mg/ml. Vial. 1 X 920 mg for SC inject.
single 23 mL in the abdomen over approx. 10 minutes every 6 months.
For adults with relapsing or primary progress. forms of multiple sclerosis.
C/I:Hypersens. Active HBV infection/ A hist. of life-threatening admin. reaction to ocrelizumab
ההשפעות האנטי-פיברוטיות של טיפולים תרופתיים חדשים לאי-ספיקת לב בחולים עם אי-ספיקת לב מתקדמת
תוצאות מבטיחות להחלפת מפרק ירך מסוג קרמיקה-על-קרמיקה
תוצאים קרדיומטבוליים בילדים עם השמנה בריאה מטבולית
תוצאות הפחתת תדירות הטיפול בריטוקסימאב במינון נמוך
בדיקה חדישה לסריקת סרטן צוואר הרחם: זיהוי אינטגרציה של HPV
חיזוי התקדמות גלאוקומה: הבינה המלאכותית עקפה את הרופאים
שימוש במעכבי SGLT2 והשפעתו על התקדמות קשריות ריאתיות
התרופה היעילה ביותר להורדת ל"ד בניתוח סינוסים אנדוסקופי
תרומת פעילות גופנית לאיכות החיים של חולות סרטן שד תחת כימותרפיה
לעלון לצרכן לחצו כאן
הודעה על עדכון בעלון של התכשירים:
Cresemba 100 mg Capsules - לפרטים נוספים לחץ כאן
Cresemba 200 mg IV - לפרטים נוספים לחץ כאן
Ixifi - לפרטים נוספים לחץ כאן
Xanax X.R - לפרטים נוספים לחץ כאן
Diflucan 50mg/ml-לפרטים נוספים לחצו כאן
Trican 200 mg-לפרטים נוספים לחצו כאן
Triflucan I.V-לפרטים נוספים לחצו כאן
IXIFI-לפרטים נוספים לחצו כאן
Monoclonal Antibody. Eculizumab 10 mg/ml. VIAL (concentrate for sol. for infus.): 1×300mg. Adult. (≥18 years of age): (PNH)-consists of a 4-week initial phase follow. by a mainten. phase: Initial phase: 600 mg admin. via a 25–45 min. IV infus. every wk. for the first 4 wks.
Mainten. phase: 900 mg admin. via a 25-45 min. IV infus. for the 5TH week, follow. by 900 mg admin. via a 25–45 min. IV infus. every 14±2 d.
In atyp. Haemolytic Uremic Synd. (aHUS) and refract. general. Myasthenia Gravis (gMG): The aHUS and refract. gMG dosing regimen for adult pts. (≥18 yrs. of age) consists of a 4 wk. init. phase follow. by a mainten. phase: Init. phase: 900 mg admin. via a 25–45 min. IV infus. every wk. for the first 4 wks.
Mainten. phase: 1,200 mg admin. via a 25–45 min. IV infus. for the fifth wk., follow. by 1,200 mg admin. via a 25–45 min. IV infus. every 14±2 d.
Paed. pts. in PNH and aHUS: Paed. pts PNH, above 11 yrs. old, and aHUS pts. with bdy. wt.≥40 kg are treated with the adult dosing recommend. respectively.
Pts. bdy. wt. 30 to<40 kg init. phase 600 mg wkly.×2, mainten. phase 900 mg at wk. 3; then 900 mg every 2 wks.
Pts. bdy. wt. 20 to<30 kg, init. phase 600 mg wkly.×2, mainten. phase 600 mg at wk. 3; then 600 mg every 2 wks.
Pts. bdy. wt. 10 to<20 kg, init. phase 600 mg wkly.×1, mainten. phase 300 mg at wk. 2; then 300 mg every 2 wks.
Pts. bdy. wt. 5 to<10 kg, init. phase 300 mg wkly.×1 mainten. phase 300 mg at wk. 2; then 300 mg every 3 wks. See lit.
Paroxysmal nocturnal haemoglobinuria (PNH).
Evidence of clinical benefit is demonstrat. in pts. with haemolysis with clinical sympt. indicative of high dis. activity, regardless of transfus. history.
Eculizumab has not been studied in clinic. trials in pts. with PNH below 11 yrs. of age.
Atypical haemolytic uremic syndr. (aHUS).
Soliris is indicated in adult. for the tmt. of: Refract. generalized myasthenia gravis (gMG) in pts. who are anti-acetylcholine receptor (AChR) antibody-positive.
C/I: Hypersens. Therapy must not be init. in pts.: with unresolved Neisseria meningitidis infect, pts. that are not current. vaccine. against Neisseria meningitidis unless they receive prophylact. tmt. with appropr. antibiot. until 2 wks. after vaccinat.
Anticonvulsant. Sulthiame 200 mg. TABS: 50. 1 1/2-4 tabs. dly. Child: 11-14
yrs: 1-3 tabs. dly.; 7-10 yrs: 11/2 tabs
dly.; 3-6 yrs: 1/2-1 tab. dly.
Epilepsy.
C/I: Acute porphyria, hyperthyroid.,
hypertens.
CCB, Local Anesthetic. Lidocaine HCl 1.5%, Nifedipine 0.3%. RECTAL CR.: 30g. Should be applied twice dly. for at least 3 wks. See lit.
Tmt. of anal fissures and proctolog. general. associate. with anal sphincter hypertonia.
C/I: Hypersens. to the active ingred., partic. to Lidocaine (& other local anesthet. with a similar amidic type structure). Presumed or ascertained preg. & lact.
Corticosteroid, Vitamin D Analogue. Betamethasone (as dipropionate) 0.5 mg/g, Calcipotriol (as monohydrate) 50 mcg/g. ALUMINIUM CAN:60 g.
Enstilar foam should be applied to the affected area once dly. The recom. tmt. period is 4 wks. The dly. max. dose should not exceed 15 g, i.e. one 60 g can should last for at least 4 d. 15 g corresponds to the amount admin. from the can if the actuator is fully depressed for approx. one minute. A two-second application delivers approx. 0.5 g. As a guide, 0.5 g of foam should cover an area of skin roughly correspond. to the surface area of an adult hand. Concomit. use with other topic. products contain. calcipotriol in addition to Enstilar: the total dose of all calcipotriol contain. products should not exceed 15 g/d. The total bdy. surf. area treated should not exceed 30%.
Ren. / hep. impair. The safety and efficacy in pts. with severe renal insuffic. or severe Hep. disord. have not been evaluated.
Ped. population:The safety and efficacy in child. below 18 yrs. have not been establish. Enstilar is not indic. for child<18 yrs. of age.
Topical tmt. of psoriasis vulgaris in adults.
C/I: Hypersens.
Pts. with erythrodermic and pustular psorias.
Pts. with known calcium metabolism disord.
Neurokinin 3 Receptor Antagonist. fezolinetant 45 mg. FC tabs. 30 X 45 mg
45 mg once daily. See lit.
tmt. of moder. to sev. vasomotor sympt. (VMS) assoc. with menopause.
C/I: Hypersens. Concom. use of moder. or strong CYP1A2 inhibit.
Known or suspect. pregn.
Moder. or sev. hepat. impairm. (Child Pugh B or C).
Monobenzone Like Depigmentation Agent. Hydroquinone 4%. GEL: 60 g. Start with 1 applic. a day for
10-15 d. on skin spots and contin. with
2 x dly morn. and even.
Lighten. skin spots.
C/I: Child. under 12 yrs., tmt. of
hyperpigmentat. resulted from chemic.
ochronosis & degeneration colloid
(colloid milium) both from employment
as cosmet.
peroxisome proliferator-activated receptor delta (PPARδ) agonist. Seladelpar 10 mg. Caps: 30 X 10 mg
Recomm. dose: 10 mg once daily.
For prim. biliary cholangitis (PBC) in combin. with ursodeoxycholic acid (UDCA) in adlts who have an inadequate resp. to UDCA alone, or as monother. in those unable to toler. UDCA.
C/I: Hypersens.
melatonin receptor agonists. Melatonin 1 mg, 5 mg. PR Tabs: 60 X 1 mg, 30 X 5mg. Recommend. Start. dose 2 mg. If inadeq. response observ., dose should be incr. to 5 mg, with a max. dose of 10 mg.
Drug should be taken once dly., 0.5-1 hr. before bedtime, with or after food.
Tmt. of insomnia in child. and adolesc. aged 2-18 with ASD and / or Smith-Magenis syndr., where sleep hygiene meas. have been insuff.
C/I: Hypersens.
